Expiration date: 11/2026
Structure and Composition:
Eye Drops 0.007%. 1 ml contains:
P-aminobenzoic acid 0.07 mg
Excipients: sodium chloride, water for injection
in bottles with dropper cap or in vials-droppers polymer (with a cover-dropper) in 5 ml in paper cartons 1 pc. or in bottles or vials-droppers polymer to 5 ml in a cardboard box 50 pcs.
Description pharmaceutical form:
Clear, colorless liquid.
Pharmachologic effect:
It is inducer of endogenous interferon, which explains one of the mechanisms of a specific antiviral activity. Has a radioprotective effect, regulates water and salt balance, stimulates regeneration processes of the cornea, has no teratogenic, mutagenic, embryotoxic action.
Pharmacokinetics:
The local administration of para-aminobenzoic acid is rapidly absorbed and exerts therapeutic effects.
Indications:
Viral conjunctivitis, keratoconjunctivitis, keratouveitis caused by Herpes simplex, Herpes zoster, adenovirus, infectious keratopathy, post-traumatic and postoperative genesis, degenerative diseases of the retina and cornea burns and eye injury, discomfort associated with eye strain and fatigue, including while wearing contact lenses.
Contraindications:
Hypersensitivity to the drug. To date clinical data regarding the use of the drug during pregnancy, lactation, and also have no children. However, the drug can be used if the expected benefits outweigh the potential risk.
Side effect:
Occasionally conjunctival hyperemia, local allergic reactions.
Drug Interactions:
In combination with the modified nucleoside (acyclovir, ganciclovir, fludarabine phosphate, etc.) And antibiotics enhanced therapeutic effect. Do not use concurrently with drugs sulfanilamidnymi (sulfacetamide), with enkada local use.
Dosage and administration:
Local: instilled into the conjunctival sac of 1-2 drops 3-8 times daily. After continuing clinical recovery instillation of 2 drops 3 times a day for 7 days.
Subconjunctival, parabulbarno, retrobulbarno: by 0.3-0.5 ml injection. The course of 3-15 injections. At surface shapes of herpetic keratitis produced through injection or one day after 2-3 days in combination with instillation of 2 drops 4-8 times a day depending on the disease. With deep shapes of herpetic keratitis first injection is carried out one time daily, then after 2-3 days in combination with instillation of 2 drops 4-8 times depending on the severity of the disease and dynamics. After recovery from the two clinical forms of the disease continue to instillation of 2 drops per day for 7-10 days.
Perivazalno: retinal dystrophy - an injection of 1 ml of a course of treatment - 10 injections.
Overdose:
Accidental ingestion of no risk of adverse side effects.
Storage conditions:
Do not freeze.
Shelf life:
After opening the package - 7 days (glass vials) and 14 days (dropper bottles of polymeric material).
